HONGWUHUAN crawler Drilling Rigs are suitable for mining, quarrying, railways, transportation, water conservancy, building materials, military and other open-air engineering drilling deep blasting, high efficiency drilling operation. Also widely used in bolt support, trench excavation, sewer engineering drilling operations. HC725.HC726.HC728.HC420.HC430.H680 series crawler DTH drilling rigs are new drilling rigs, developed to meet the market demand, excellent performance, flexible operation, full features, more wider adaptability, high cost performance. In order to adapt to different working conditions and customers` requirements, various specifications of diesel engines and motors are used to meet various requirements.
Crawler Drilling Rig,Crawler Water Well Drilling Rig,Hydraulic Crawler Drilling Rig,Crawler Anchor Drilling Rig Quzhou Able Machinery Equipment CO., LTD. , http://www.ablejx.com
Insulin pump therapy or continuous subcutaneous injection of insulin (CSII) can replace the single injection of insulin that must be infused several times a day. This therapy is increasingly favored. According to the CSII treatment, diabetic patients need to be connected to a programmable syringe pump. The syringe pump is connected to a reservoir, and insulin is injected from the reservoir into the subcutaneous tissue of the human body. Continuous infusion throughout the day is more like insulin secretion from the pancreas. the process of.
This highly miniaturized disposable insulin syringe pump combines Debiotech's insulin infusion technology with ST's large-scale manufacturing microfluidic chip production capacity. Microfluidic technology electronically controls the flow of very small amounts of liquid. This syringe pump marks a major step forward in the development and application of CSII therapy, and this cutting-edge technology will be applied to other biochemical applications.
Today, existing insulin syringe pumps are the size of a pager. The new Debiotech miniaturized MEMS product, manufactured by ST, is about a quarter of the size of an existing syringe pump and is worn on the human body in the form of a skin patch that is almost invisible to the human eye. In the past, patients need to pay attention to the proper installation position of the syringe pump, and also hide the pump under the clothes. The small size of the new product no longer makes the patient worry.
In addition, nano-pumps using MEMS technology can precisely control the injection dose of insulin required by doctors. The accuracy of the dose is a key factor in determining the level of efficacy, and it also helps to reduce the negative effects of long-term infusion of the drug. The nano pump's control accuracy for liquid infusion can reach nanoliters, which is very close to human insulin infusion. The product prevents overdose and detects under-medication, blockages, air bubbles and other potential malfunctions in the syringe pump to further protect the patient. In addition, as a one-off product using large-scale semiconductor manufacturing technology, the cost of this MEMS-based nano syringe pump is also very low, so patients or health care systems do not have to pay for the upfront investment common to existing syringe pump solutions.
The insulin injection pump developed by Debiotech and industrialized by ST marks the first application of microfluidic MEMS technology to the field of diabetes treatment. The functional samples of the nanopump have been put into production, and the partners expect to supply fully industrialized products sold as disposable reservoirs for the designated market after 2008. Debiotech will then sell products in the form of licenses to major manufacturers in the medical device market.
The industrialization of new products will make full use of the manufacturing experience that ST has accumulated in the biochemical market. Other biotech projects in ST Microfluidics also include the In-Check on-chip experimental platform, which is currently used primarily to detect sepsis and avian influenza.
“ST is continuously strengthening its semiconductor manufacturing process and accumulating experience in microfluidic biotechnology applications, which has made it possible for us to extend the lives of millions of people around the world,†said ST Vice President and Microfluidics. Anton Hofmeister, general manager of the department, said, "In the process of cooperation with Debiotech, the leading manufacturer of biochemical application development, we are mainly responsible for the industrialization of nano insulin injection pumps. The goal of this project is to completely break the therapeutic limits of diabetes."
“Our partnership with ST represents a major step forward in the manufacturing of nano syringe pumps, enabling new products to be produced and sold in huge markets at a cost consistent with disposables. ST is the world's leading MEMS Manufacturers, we are very excited to be working with ST, we will be dedicated to a diabetic patient, providing a new treatment for diabetes, one of the most serious diseases of this century.†DebiotechSA President and Chief Executive Officer Dr. Frederic Neftel said.
Supplementary explanation
About 250 million people worldwide are currently suffering from diabetes. With population growth, aging and lifestyle changes, the number of patients is expected to continue to increase over the next decade. If not treated properly, diabetes can lead to cardiovascular disease, kidney failure, blindness, nerve damage and death. Diabetes is one of the leading causes of death in Western developed countries.
The insulin injection pump treatment market is growing at a rapid rate: According to HSBC1, before 2009, the global insulin injection pump treatment market is expected to grow from $800 million in 2004 to $1.6 billion.
Recently, Debiotech and STMicroelectronics announced that they have signed a strategic cooperation agreement to manufacture and sell a unique micro insulin syringe pump. This nanopump is an innovative concept based on microfluidic MEMS (Micro Electro Mechanical Systems) technology. The design principle is to install a micro syringe pump on a disposable skin patch to continuously infuse insulin into diabetic patients. This nano pump will help to greatly increase the availability of new technologies, treatment efficiency and the quality of life of people with diabetes. The original technology of the product was awarded the 2006 Swiss Technology Award, and the agreement signed today brings the technology closer to the goal of industrialization.